Search for Stocks /

Hindustan Organic Chemicals Ltd Q3 FY26 – ₹147 Cr Sales, ₹3.88 Cr Loss, 0.20x Book Value & A Supreme Court Twist


1. At a Glance – The PSU That Refuses To Die

Market Cap: ₹206 Cr.
Current Price: ₹30.6
Book Value: ₹152
Price to Book: 0.20x
ROE: -21.6%
ROCE: -5.20%
Q3 FY26 Sales: ₹147 Cr
Q3 FY26 PAT: -₹3.88 Cr

This is what happens when a 1960-born PSU chemical company survives everything — oil shocks, policy shocks, management shocks, and finally… Supreme Court shocks. HOCL is trading at just 0.20 times book value. That means the market is valuing ₹152 worth of assets at ₹30.6. Either this is a hidden gem… or the market is politely saying, “Bhai, assets toh hain, profits kahan hai?”

The latest quarterly results show revenue of ₹147 Cr and a net loss of ₹3.88 Cr. Loss reduced significantly YoY, but still loss. Meanwhile, the Government waived ₹1,351 crore of dues earlier this year. That’s not restructuring. That’s financial CPR.

Now the big question: Is this a turnaround candidate… or a chemical museum piece still open for visitors?

Let’s investigate.


2. Introduction – The Government’s Chemical Baby

HOCL was incorporated in 1960. Back when India was building steel plants and dreaming in Five-Year Plans. It is under the Ministry of Chemicals and Fertilizers and the Government of India holds 58.78%.

So yes — this is not your average promoter-run company. This is India’s chemical uncle.

HOCL is the second largest producer of Phenol and Acetone in India. It also manufactures Hydrogen Peroxide. Raw materials? Benzene and LPG from petroleum refineries. Which means margins depend heavily on crude oil economics.

But here’s the spicy part.

In March 2025, the Government waived ₹1,351.38 crore of dues. Imagine your bank calling and saying, “Loan maaf.” That’s what happened here.

And then the Supreme Court directed HOCL to pay ₹43.50 Cr disputed rent to a landlord. Corporate drama never disappoints.

Add to that:

  • Land sale to BPCL for ₹37.53 Cr
  • Closure of subsidiary Hindustan Fluorocarbons Ltd
  • Capital reduction by cancelling ₹270 crore preference shares

This isn’t just a chemical company.

This is a financial thriller series.

Are we looking at a revival? Or is this restructuring just cosmetic surgery?

Let’s decode.


Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →